NASDAQ:BCRX - BioCryst Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.00 -0.12 (-1.48 %) (As of 03/19/2019 11:31 AM ET)Previous Close$8.12Today's Range$7.96 - $8.1152-Week Range$4.53 - $9.95Volume5,389 shsAverage Volume834,703 shsMarket Capitalization$881.44 millionP/E Ratio-8.17Dividend YieldN/ABeta1.81 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. Receive BCRX News and Ratings via Email Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BCRX Previous Symbol CUSIP09058V10 CIK882796 Webwww.biocryst.com Phone919-859-1302Debt Debt-to-Equity Ratio0.57 Current Ratio1.65 Quick Ratio1.62Price-To-Earnings Trailing P/E Ratio-8.17 Forward P/E Ratio-6.72 P/E GrowthN/A Sales & Book Value Annual Sales$20.65 million Price / Sales42.68 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book17.78Profitability EPS (Most Recent Fiscal Year)($0.98) Net Income$-101,250,000.00 Net Margins-490.25% Return on Equity-175.83% Return on Assets-66.71%Miscellaneous EmployeesN/A Outstanding Shares110,180,000Market Cap$881.44 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions What is BioCryst Pharmaceuticals' stock symbol? BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX." How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced its quarterly earnings data on Monday, March, 4th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. The biotechnology company had revenue of $2.73 million for the quarter, compared to analysts' expectations of $2.39 million. BioCryst Pharmaceuticals had a negative return on equity of 175.83% and a negative net margin of 490.25%. View BioCryst Pharmaceuticals' Earnings History. When is BioCryst Pharmaceuticals' next earnings date? BioCryst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for BioCryst Pharmaceuticals. What price target have analysts set for BCRX? 8 equities research analysts have issued 1-year target prices for BioCryst Pharmaceuticals' stock. Their forecasts range from $8.50 to $16.00. On average, they expect BioCryst Pharmaceuticals' share price to reach $12.9167 in the next year. This suggests a possible upside of 61.3% from the stock's current price. View Analyst Price Targets for BioCryst Pharmaceuticals. What is the consensus analysts' recommendation for BioCryst Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioCryst Pharmaceuticals. Has BioCryst Pharmaceuticals been receiving favorable news coverage? Press coverage about BCRX stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioCryst Pharmaceuticals earned a news impact score of 1.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of BioCryst Pharmaceuticals' key competitors? Some companies that are related to BioCryst Pharmaceuticals include China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY) and Alector (ALEC). What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), Celgene (CELG), Opko Health (OPK), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Sarepta Therapeutics (SRPT) and Actinium Pharmaceuticals (ATNM). Who are BioCryst Pharmaceuticals' key executives? BioCryst Pharmaceuticals' management team includes the folowing people: Mr. Jon P. Stonehouse, CEO, Pres & Director (Age 58)Mr. Thomas R. Staab II, CFO, Principal Accounting Officer, Sr. VP & Treasurer (Age 51)Dr. William P. Sheridan, Chief Medical Officer & Sr. VP (Age 64)Dr. Yarlagadda S. Babu, Sr. VP of Drug Discovery (Age 66)Ms. Lynne M. Powell, Chief Commercial Officer & Sr. VP (Age 52) Who are BioCryst Pharmaceuticals' major shareholders? BioCryst Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include RA Capital Management LLC (9.72%), BlackRock Inc. (8.07%), Great Point Partners LLC (6.95%), Jennison Associates LLC (3.46%), FMR LLC (2.73%) and D. E. Shaw & Co. Inc. (1.37%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Fred E Cohen, Lynne Powell, Steve Aselage, Thomas R Staab II and William P Sheridan. View Institutional Ownership Trends for BioCryst Pharmaceuticals. Which institutional investors are selling BioCryst Pharmaceuticals stock? BCRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Great Point Partners LLC, D. E. Shaw & Co. Inc., Two Sigma Investments LP, Hudson Bay Capital Management LP, Royce & Associates LP and Jennison Associates LLC. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last year include Alane P Barnes, Lynne Powell, Thomas R Staab II and William P Sheridan. View Insider Buying and Selling for BioCryst Pharmaceuticals. Which institutional investors are buying BioCryst Pharmaceuticals stock? BCRX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Emory University, Bank of New York Mellon Corp, Geode Capital Management LLC, Geode Capital Management LLC, BlackRock Inc., Rhumbline Advisers and Metropolitan Life Insurance Co. NY. View Insider Buying and Selling for BioCryst Pharmaceuticals. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioCryst Pharmaceuticals' stock price today? One share of BCRX stock can currently be purchased for approximately $8.01. How big of a company is BioCryst Pharmaceuticals? BioCryst Pharmaceuticals has a market capitalization of $882.54 million and generates $20.65 million in revenue each year. The biotechnology company earns $-101,250,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. What is BioCryst Pharmaceuticals' official website? The official website for BioCryst Pharmaceuticals is http://www.biocryst.com. How can I contact BioCryst Pharmaceuticals? BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at 919-859-1302 or via email at [email protected] MarketBeat Community Rating for BioCryst Pharmaceuticals (NASDAQ BCRX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 368 (Vote Outperform)Underperform Votes: 340 (Vote Underperform)Total Votes: 708MarketBeat's community ratings are surveys of what our community members think about BioCryst Pharmaceuticals and other stocks. Vote "Outperform" if you believe BCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: Why do companies issue convertible shares?